Im Clone Systems, Inc.

GPTKB entity

Statements (61)
Predicate Object
gptkbp:instance_of gptkb:Company
gptkbp:bfsLayer 4
gptkbp:bfsParent gptkb:Im_Clone_Systems
gptkbp:acquired gptkb:Eli_Lilly_and_Company
gptkbp:acquisition gptkb:2008
$6.5 billion
gptkbp:approves gptkb:FDA
gptkbp:business_model biopharmaceuticals
gptkbp:ceo M. Sean Mc Carthy
gptkbp:clinical_trial ongoing
positive
multiple phases
Phase III
gptkbp:collaborations ongoing
academic institutions
biotech firms
gptkbp:committee established
gptkbp:economy gptkb:Company
gptkbp:employees approximately 300
gptkbp:financial_performance strong
gptkbp:founded gptkb:1984
gptkb:New_York
gptkbp:founder David Sidransky
gptkbp:grants received
gptkbp:headcount gptkb:300
gptkbp:headquarters gptkb:Borough
gptkb:New_York
gptkbp:healthcare gptkb:2004
oncology
https://www.w3.org/2000/01/rdf-schema#label Im Clone Systems, Inc.
gptkbp:industry Pharmaceuticals
gptkbp:invention multiple patents in oncology
gptkbp:investment oncology
publicly traded
various institutional investors
R& D
gptkbp:language_of_instruction diverse
gptkbp:location gptkb:United_States
gptkbp:market gptkb:Erbitux
gptkbp:market_cap approximately $6 billion
gptkbp:marketing_strategy focused on oncology
gptkbp:notable_achievement FDA approval for Erbitux in 2004
gptkbp:notable_allies pharmaceutical companies
gptkbp:part_of Eli Lilly and Company group
gptkbp:partnership research institutions
gptkbp:partnerships various pharmaceutical companies
gptkbp:products gptkb:Erbitux
ongoing
monoclonal antibodies
multiple candidates
gptkbp:research_and_development significant investment
gptkbp:research_areas oncology
gptkbp:research_focus gptkb:healthcare_organization
EGFR inhibitors
gptkbp:revenue approximately $1 billion
gptkbp:subsidiary Im Clone Systems, LLC
gptkbp:symbol IMCL
gptkbp:traded_on gptkb:NASDAQ
gptkbp:treatment cancer therapies
gptkbp:type gptkb:football_club
gptkbp:website www.imclone.com